Fusion Pharmaceuticalsinc Stock Filter Stocks by Fundamentals
| FUSN Stock | USD 21.48 0.10 0.47% |
Fusion PharmaceuticalsInc fundamentals help investors to digest information that contributes to Fusion PharmaceuticalsI's financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion PharmaceuticalsI's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion PharmaceuticalsI stock.
Fusion | Shares Owned by Institutions |
Fusion PharmaceuticalsI Institutional Holders
Institutional Holdings refers to the ownership stake in Fusion PharmaceuticalsI that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fusion PharmaceuticalsI's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fusion PharmaceuticalsI's value.| Shares | Artal Group S A | 2023-12-31 | 1 M | Blair William & Co | 2023-12-31 | 993.9 K | Wellington Management Company Llp | 2023-12-31 | 744.5 K | 1832 Asset Management L.p | 2023-12-31 | 734.3 K | Eagle Health Investments Lp | 2023-12-31 | 579.8 K | Millennium Management Llc | 2023-12-31 | 578.1 K | Ikarian Capital, Llc | 2023-12-31 | 500 K | Blackrock Inc | 2023-12-31 | 419.8 K | Adage Capital Partners Gp Llc | 2023-12-31 | 400 K | Federated Hermes Inc | 2023-12-31 | 10.9 M | Avidity Partners Management Lp | 2023-12-31 | 6.5 M |
Fusion Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (54.04) % | ||||
| Current Valuation | 1.68 B | ||||
| Shares Outstanding | 85.06 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 80.44 % | ||||
| Number Of Shares Shorted | 3.95 M | ||||
| Price To Book | 8.13 X | ||||
| Price To Sales | 874.50 X | ||||
| Revenue | 2.07 M | ||||
| Gross Profit | (57.43 M) | ||||
| EBITDA | (97.89 M) | ||||
| Net Income | (94.9 M) | ||||
| Cash And Equivalents | 198.42 M | ||||
| Cash Per Share | 4.57 X | ||||
| Total Debt | 50.33 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 17.89 X | ||||
| Book Value Per Share | 2.85 X | ||||
| Cash Flow From Operations | (81.8 M) | ||||
| Short Ratio | 3.65 X | ||||
| Earnings Per Share | (1.40) X | ||||
| Target Price | 21.13 | ||||
| Number Of Employees | 101 | ||||
| Beta | -0.72 | ||||
| Market Capitalization | 1.83 B | ||||
| Total Asset | 285.84 M | ||||
| Retained Earnings | (376.76 M) | ||||
| Working Capital | 227.18 M | ||||
| Net Asset | 285.84 M |
About Fusion PharmaceuticalsI Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion PharmaceuticalsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion PharmaceuticalsI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion PharmaceuticalsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Fusion PharmaceuticalsI Investors Sentiment
The influence of Fusion PharmaceuticalsI's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Fusion. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Fusion PharmaceuticalsI's public news can be used to forecast risks associated with an investment in Fusion. The trend in average sentiment can be used to explain how an investor holding Fusion can time the market purely based on public headlines and social activities around Fusion PharmaceuticalsInc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Fusion PharmaceuticalsI's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Fusion PharmaceuticalsI's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Fusion PharmaceuticalsI's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Fusion PharmaceuticalsI.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fusion PharmaceuticalsI in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fusion PharmaceuticalsI's short interest history, or implied volatility extrapolated from Fusion PharmaceuticalsI options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fusion PharmaceuticalsI Piotroski F Score and Fusion PharmaceuticalsI Altman Z Score analysis. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Fusion Stock analysis
When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.